GLP-1

GLP-1 Muscle Loss: How to Protect Lean Mass During Weight Loss

How much of the weight lost on semaglutide or tirzepatide is lean mass, what the DXA substudies show, and how protein and resistance training help protect muscle.

GLP-1 cost: Medicare, brand-name direct and compounded →GLP-1 with insurance or Medicare ($25 / $50 routes) →Online GLP-1 providers compared →

· 6 min read ·

⚕️ Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any peptide.

⚕️ Medical Disclaimer

⚕️ Medical Disclaimer: This is general education, not medical advice. Written by the Kymata Health editorial team; medical review pending. Talk with your prescriber before changing your diet, exercise or medicines. Evidence grades: A = several randomized trials or a meta-analysis; B = at least one randomized trial; C = small or pilot human data, or mechanism only; D = animal or cell data, or anecdote.

How Much of the Weight Lost Is Lean Mass?

Weight loss by any method removes some lean mass along with fat. "Lean mass" includes not only muscle but also organs, bone, body fluids and the water inside fat tissue. So a drop in lean mass is not the same as an equal drop in muscle (Neeland et al., Diabetes Obes Metab 2024; PMID: 38937282).

SURMOUNT-1 body-composition substudy (Look et al., Diabetes Obes Metab 2025; PMID: 39996356): in 160 adults scanned at baseline and week 72, about 75% of the weight lost on tirzepatide was fat and about 25% was lean mass. The split was about the same in the placebo group, which lost much less weight. Evidence: B (randomized trial substudy).

STEP 1 DXA substudy (Wilding et al., N Engl J Med 2021; PMID: 33567185): people on semaglutide 2.4 mg lost about 10.4 kg of fat and 6.9 kg of lean mass, roughly 60% fat and 40% lean, as summarized in the SURMOUNT-1 substudy paper above. Evidence: B (randomized trial substudy).

Across GLP-1 studies, reported lean-mass shares vary widely with the population and the measuring method (PMID: 38937282). Losing some lean mass is expected. The aim is to keep as much muscle and strength as you can while you lose fat.

Preservation Strategies

Protein: with a smaller appetite it is easy to under-eat protein. Include a protein food at every meal, starting with breakfast. Ask your clinician or a registered dietitian what daily target fits you, especially if you have kidney disease.

Resistance training 2-3 times a week, gradually making it harder over time, gives your muscles a reason to stay while you lose fat. Bands, machines or bodyweight exercises all count.

Creatine monohydrate is sometimes used alongside resistance training. It has not been studied specifically in people taking GLP-1 medicines, so check with your clinician before adding it. Evidence for these strategies in GLP-1 users specifically: C.

❓ Frequently Asked Questions

How much muscle do you lose on semaglutide?▼
In the STEP 1 DXA substudy, about 40% of the weight lost on semaglutide 2.4 mg was lean mass (PMID: 33567185, as summarized in PMID: 39996356). Lean mass includes organs and water as well as muscle, so muscle loss itself is smaller than that figure. In the SURMOUNT-1 substudy, about 25% of the weight lost on tirzepatide was lean mass (PMID: 39996356).
How much protein should I eat to protect muscle on a GLP-1?▼
It depends on your body size, activity and kidney health. Aim for a protein food at every meal, and ask your clinician or a registered dietitian what daily target fits you.

📖 References

  1. Look M, et al. “Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.” Diabetes Obes Metab (2025). PMID: 39996356
  2. Wilding JPH, et al. “Once-weekly semaglutide in adults with overweight or obesity (STEP 1).” N Engl J Med (2021). PMID: 33567185
  3. Neeland IJ, Linge J, Birkenfeld AL. “Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.” Diabetes Obes Metab (2024). PMID: 38937282

Featured in clinical protocols

Related articles

Share this article

Found this useful? Let others know too.